Phase II · 2023
Triple–Hormone-Receptor Agonist Retatrutide for Obesity
Jastreboff AM, Kaplan LM, Frías JP, et al. · New England Journal of Medicine
24.2% mean weight loss at 48 weeks on 12 mg weekly — the largest figure reported for any pharmacologic agent to date.
Key findings
- Weight loss had not plateaued at 48 weeks
- Hepatic steatosis resolved in most participants in the imaging substudy
- Dose-dependent GI adverse events and modest heart-rate increase
Limitations
Phase II sample of 338; long-term safety and cardiovascular outcomes are unknown pending Phase III.